These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 25983297

  • 1. Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer.
    Dębska-Szmich S, Kusińska R, Czernek U, Szydłowska-Pazera K, Habib-Lisik M, Piekarski JH, Olas E, Kulig A, Ułańska M, Kalinka-Warzocha E, Potemski P.
    Postepy Hig Med Dosw (Online); 2015 May 05; 69():586-97. PubMed ID: 25983297
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May 05; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A, Lazaridis G, Koliou GA, Kouvatseas G, Christodoulou C, Pectasides D, Kotoula V, Batistatou A, Bobos M, Tsolaki E, Papadopoulou K, Pentheroudakis G, Papakostas P, Pervana S, Petraki K, Chrisafi S, Razis E, Psyrri A, Bafaloukos D, Kalogeras KT, Kalofonos HP, Fountzilas G.
    PLoS One; 2018 May 05; 13(12):e0207707. PubMed ID: 30521571
    [Abstract] [Full Text] [Related]

  • 4. Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
    Kanomata N, Kurebayashi J, Moriya T.
    Med Mol Morphol; 2019 Jun 05; 52(2):106-113. PubMed ID: 30317526
    [Abstract] [Full Text] [Related]

  • 5. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment.
    Park YH, Jung HA, Choi MK, Chang W, Choi YL, Do IG, Ahn JS, Im YH.
    Br J Cancer; 2014 Jan 21; 110(2):384-91. PubMed ID: 24346286
    [Abstract] [Full Text] [Related]

  • 6. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Katayama K, Koga T, Kurashita K, Hasegawa S, Todoroki H, Kai Y, Ohi Y, Toyoshima S, Arima N, Mitsuyama S, Tamura K.
    Oncology; 2017 Jan 21; 93(1):51-61. PubMed ID: 28478451
    [Abstract] [Full Text] [Related]

  • 7. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K, Kashiwagi S, Goto W, Asano Y, Morisaki T, Fujita H, Takashima T, Ohsawa M, Hirakawa K, Ohira M.
    Anticancer Res; 2018 Apr 21; 38(4):2285-2294. PubMed ID: 29599351
    [Abstract] [Full Text] [Related]

  • 8. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.
    Green AR, Barros FF, Abdel-Fatah TM, Moseley P, Nolan CC, Durham AC, Rakha EA, Chan S, Ellis IO.
    Breast Cancer Res Treat; 2014 May 21; 145(1):33-44. PubMed ID: 24706169
    [Abstract] [Full Text] [Related]

  • 9. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C, Yi X, Liu W, Han T, Liu Z, Ding Z, Zheng Z, Piao Y, Yuan J, Han Y, Xie M, Xie X.
    BMC Cancer; 2014 Nov 24; 14():869. PubMed ID: 25417825
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G.
    Breast Cancer Res Treat; 2011 Jul 24; 128(2):447-56. PubMed ID: 21594665
    [Abstract] [Full Text] [Related]

  • 11. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
    Wang Y, Liu Y, Du Y, Yin W, Lu J.
    Curr Med Res Opin; 2013 Jun 24; 29(6):633-42. PubMed ID: 23574264
    [Abstract] [Full Text] [Related]

  • 12. PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
    Stern HM, Gardner H, Burzykowski T, Elatre W, O'Brien C, Lackner MR, Pestano GA, Santiago A, Villalobos I, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Nuciforo P, Bee V, Mackey J, Slamon DJ, Press MF.
    Clin Cancer Res; 2015 May 01; 21(9):2065-74. PubMed ID: 25649019
    [Abstract] [Full Text] [Related]

  • 13. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.
    Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, Santoni-Rugiu E, Andersson M, Ewertz M.
    Ann Oncol; 2012 Aug 01; 23(8):2034-2042. PubMed ID: 22172323
    [Abstract] [Full Text] [Related]

  • 14. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
    Okutur K, Bassulu N, Dalar L, Aydin K, Bozkurt M, Pilanci KN, Dogusoy GB, Tecimer C, Mandel NM, Demir G.
    Asian Pac J Cancer Prev; 2015 Aug 01; 16(7):2645-51. PubMed ID: 25854340
    [Abstract] [Full Text] [Related]

  • 15. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
    Berghoff AS, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M, Streubel B, Dubsky P, Gnant M, Fitzal F, Zielinski CC, Birner P.
    Breast; 2014 Oct 01; 23(5):637-43. PubMed ID: 25017122
    [Abstract] [Full Text] [Related]

  • 16. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
    Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L.
    Ann Oncol; 2009 Apr 01; 20(4):648-54. PubMed ID: 19188134
    [Abstract] [Full Text] [Related]

  • 17. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
    Koo DH, Lee HJ, Ahn JH, Yoon DH, Kim SB, Gong G, Son BH, Ahn SH, Jung KH.
    Tumour Biol; 2015 Aug 01; 36(8):5865-71. PubMed ID: 25725586
    [Abstract] [Full Text] [Related]

  • 18. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L.
    Oncotarget; 2015 Nov 10; 6(35):37269-80. PubMed ID: 26452030
    [Abstract] [Full Text] [Related]

  • 19. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S, Staff S, Kallioniemi A, Tanner M, Isola J.
    BMC Cancer; 2018 Oct 26; 18(1):1045. PubMed ID: 30367623
    [Abstract] [Full Text] [Related]

  • 20. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
    Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, Köstler WJ, Huang W, Weidler JM, Ali S, Newton A, Fuchs EM, Paquet A, Singer CF, Horvat R, Jin X, Banerjee J, Mukherjee A, Tan Y, Shi Y, Chenna A, Larson J, Lie Y, Sherwood T, Petropoulos CJ, Williams S, Winslow J, Parry G, Bates M.
    Breast Cancer Res Treat; 2013 Aug 26; 141(1):43-53. PubMed ID: 23959396
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.